An accurate and precise method to determine glucose concentration in whole blood is presented. The method, based on isotope dilution gas chromatography-mass spectrometry (ID GC-MS), was developed to be used as a Reference Method for determining glucose concentration in capillary or venous whole blood. Blood samples and standards are pipetted manually with "microcap" micropipettes, which makes it possible to collect samples even at the patient's bedside. Glucose is quantified as its aldononitrile pentaacetate. 
During the past 10 years, there has been a fast growth of new glucose meters for monitoring blood glucose. These instruments are frequently used at home, at the physician's office, and at diabetic clinics. Although they are generally checked with a routine clinical laboratory method for glucose determination, there is no common basis for comparing the accuracy and precision of these instruments [1] . The importance of reliable methods for self-monitoring of blood glucose is obvious from the results of the Diabetes Control and Complications Trial [2] .
The technique of isotope dilution gas chromatographymass spectrometry (ID GC-MS) has been used in many efforts to establish Reference Methods or Definitive Methods for glucose in serum [3] [4] [5] [6] . This technique has also been used since the mid-1970s by the US National Institute of Standards and Technology (NIST) in their development of such methods for glucose and other endogenous analytes in serum [7, 8] . Pioneers in the field of establishing Reference Methods and Definitive Methods were Bjö rkhem et al. [9] , who developed an ID GC-MS method for glucose in serum so as to evaluate routine methods for glucose determination.
All the currently published Reference Methods and Definitive Methods for glucose are applicable to measurement of glucose in serum and not in whole blood [10] . The Reference Methods and Definitive Methods used by the NIST and others [3] [4] [5] for determination of glucose in serum all have very high accuracy and precision. This high accuracy and precision is in part achieved by the way the samples and standards are added in the methods. Serum and standards are measured gravimetrically, and the serum samples are bracketed by internal standard and standard samples having a concentration of glucose just above and below that of the serum sample. This requires preliminary quantification of glucose in the sample to find a proper concentration for the internal standard and the glucose standard.
We describe here an ID GC-MS method for glucose in whole blood. The derivatization of glucose is essentially performed as described by Stö kl and Reinauer [5] and Magni et al. [6] . The blood and standard solutions are sampled volumetrically. Instead of the bracketing technique presented by Cohen et al. [11] , we use six standard solutions of glucose, ranging from 1.0 to 20.0 mmol/L, and a fixed concentration of the internal standard,
We also present the results of an accuracy assessment of the HemoCue blood glucose analyzer in comparison with the ID GC-MS method as a Reference Method. The glucose was measured by split-sample technique in capillary blood of 67 diabetic patients and 62 nondiabetic persons.
Materials and Methods apparatus
GC-MS. The instrumentation consisted of an HP 5890 Series II gas chromatograph with an HP 7673 autosampler and a column inserted directly into the ion source of an HP MSD 5970 mass spectrometer (Hewlett-Packard, Palo Alto, CA). The gas chromatograph was equipped with a 25 m ϫ 0.25 mm CP-Sil-13 CB WCOT fused-silica column coated with a film 0.20 m thick (Chrompack International BV, Middelburg, The Netherlands). The carrier gas was helium at a head pressure of 45 kPa. The injector was used in the splitless mode and its temperature was kept at 270°C. The oven temperature was ramped from 80°C to 300°C at 20°C/min. In these conditions, the derivatives of glucose and [ 13 C 6 ]glucose were eluted after ϳ11.4 min. The transfer line of the column to the ion source was kept at 260°C. The mass spectrometer was calibrated with perfluorotributylamine through the "Standard Autotune" program of the "Chem Station" software (HewlettPackard). The analyses were carried out by selected ion monitoring, with acquisition of ions at m/z 314.0 and 242.1 for unlabeled glucose and ions at m/z 319.0 and 246.1 for 13 C-labeled glucose. The acquisitions for all four ions together were done during scan cycles of 0.17 s. These conditions meant that ϳ30 scans were performed during elution of the glucose peak. .0 mmol/L glucose solution and diluting it to 100 mL with water. These standard solutions were divided into portions and stored at Ϫ20°C; repeated assays after various storage periods showed them to be stable for at least 6 months under these conditions. To determine the between-run CV, we analyzed Seronorm (Nycomed Pharma AS, Oslo, Norway; lot no. 182) as a control with each series of blood samples. For the low and high range of glucose concentration, Pathonorm L and Pathonorm H (Nycomed; lot nos. 010026 and 503418, respectively) were analyzed. To assess the accuracy of the method, we used SRM 909b Level I from NIST.
Internal standard solution.
[ 13 C 6 ]Glucose (Cambridge Isotope Labs., Andover, MA) was used as an internal standard. The solution was prepared by weighing 9.31 mg of [ 13 C 6 ]glucose and adding deionized water to a final volume of 50 mL, giving a concentration of 1.0 mmol/L. The solution was stored at Ϫ20°C in 5-mL portions.
Chemicals. All chemicals were of analytical grade. Pyridine was from May & Baker (Dagenham, UK) and acetic anhydride, methanol, and hydroxylamine hydrochloride were purchased from Fluka Chemie (Buchs, Switzerland). The pyridine was distilled before use and stored over KOH pellets.
analytical procedure Blood samples were collected from patients with diabetes mellitus and from apparently healthy nondiabetic individuals. The sampling was approved by the Committee for Medical Ethics at the University Hospital of Linkö ping and was conducted in accordance with the rules of the Committee. Capillary blood (50 L) was taken with a microcap and immediately transferred to a tube containing 200 L of [ 13 C 6 ]glucose, 1.0 mmol/L. The microcap was washed five times with the internal standard solution and the tube was thoroughly shaken. The sample was left on the bench for 1-2 h, and 1 mL of methanol was added for deproteinization. After mixing the sample, we let it stand for 30 -45 min and then centrifuged it for 10 min at 1000g. A portion (0.5 mL) of the methanol/water phase Clinical Chemistry 43, No. 5, 1997 was taken to dryness under a stream of nitrogen on a heating block at 50°C. The glucose and [ 13 C 6 ]glucose in the sample were then converted to aldononitrile derivatives by adding 150 L of 0.2 mol/L hydroxylamine hydrochloride solution in pyridine and heating at 90°C for 40 min. After cooling, the derivatives were acetylated by addition of 200 L of acetic anhydride, followed by heating at 90°C for 60 min. The samples were then evaporated just to dryness under nitrogen (at 50°C), and the residues were dissolved in 0.5 mL of chloroform. Before the GC-MS analysis, 15 L of the solution was diluted with 135 L of chloroform in small glass vials that were then capped with polytetrafluoroethylene septum caps. By dissolving the samples in 0.5 mL of chloroform and diluting the samples an additional 10-fold in chloroform, we could detect no deterioration of peak shape from eventual residual hydroxylamine, not even after several hundred injections. The vials were loaded into the autosampler, which was programed to inject 1 L of each sample into the gas chromatograph. The standards and the controls were treated the same as the blood samples. A calibration curve was produced and a control sample was included in every batch of blood samples measured. All samples, standards, and controls were measured singly, and results were quantified by measuring the peak areas for m/z 314.0 and 242. 
other studies
Influence of glycolysis. The effect of the glycolysis in the analysis procedure was tested on three different occasions by collecting into EDTA K 3 -containing tubes a blood sample from nondiabetic individuals. Blood aliquots were taken from the tubes with 50-L microcaps and transferred to seven small plastic tubes containing 200 L of internal standard solution. After the microcaps were washed five times in the internal standard solution, each sample in the plastic tubes was mixed. Methanol was then added to the tubes after 5, 15, 30, 60, 120, 180, or 240 min. The samples were then analyzed as described in the preceding section.
Estimation of accuracy, precision, and specificity. The accuracy of the method was assessed by measuring glucose in SRM 909b Level I with five analyses at two different occasions with use of both glucose from Mallinckrodt and the NIST SRM 917b as standard material. Within-run imprecision was determined by multiple analyses of whole blood, Seronorm, Pathonorm L, and Pathonorm H in the same series. The between-run imprecision was calculated from independent single analyses of the control samples on different days. Seronorm was analyzed as a single sample on 36 different days within a period of 10 months; Pathonorm L and Pathonorm H were measured as single samples on 19 and 21 different days, respectively. The within-run and between-run imprecision was determined so as to include all parts of the analysis, i.e., sample collection, sample preparation, and quantification of glucose with the GC-MS instrument. Assay specificity was demonstrated by analyzing a sample of EDTA K 3 -treated blood that had been gently mixed for a little more than 3 days. During this time, all the glucose was consumed by glycolysis, so that any interfering substances present should be disclosed in the chromatogram. The imprecision in the two pipetting steps in the method was determined by performing multiple weighings of the 50-L microcaps filled with water and by weighing the amount of water delivered by the 40 -200-L adjustable micropipette.
Linearity. We used a standard curve over the 1.0 -20.0 mmol/L concentration range and checked the linearity by linear regression fit.
HemoCue/ID GC-MS comparison.
The HemoCue blood glucose analyzer is a bedside or near-patient analyzer with dedicated cuvettes; glucose dehydrogenase, mutarotase, and diaphorase act on the sample in connection with a color-generating reagent. The glucose is measured after the erythrocytes have been lysed in the cuvette. The analytical principle was described by Banauch et al. [12] .
The recommended measurement range for the HemoCue blood glucose analyzer is 0 -22.2 mmol/L. The HemoCue analyzer is calibrated by the manufacturer against an automated glucose dehydrogenase method and a Yellow Springs Instruments glucose analyzer (YSI Ltd., Hampshire, UK). Each individual analyzer is equipped with a control cuvette to assure the stability of the calibration. For an analysis to be acceptable, the result for the control cuvette may not deviate ϾϮ 0.3 mmol/L from the target value. The effect of hematocrit on the HemoCue blood glucose analyses has been studied by Wiener [13] , who saw no appreciable effect from variations in the hematocrit.
In the comparison study, the HemoCue instrument with disposable cuvettes was carried to the patients, as were small plastic tubes containing 200 L of [ 13 C 6 ]glucose, 1.0 mmol/L (used as sampling tubes for the ID GC-MS method). Capillary blood was collected into the HemoCue cuvette, which was inserted into the photometer to read the glucose concentration. Without delay after the cuvette sampling, capillary blood was also taken into a 50-L microcup and transferred at once into the 200-L solution of internal standard. The 50-L microcup was washed five times with the [ 13 C 6 ]glucose solution, and the sample was thoroughly mixed. These tubes (containing the mixture of blood and internal standard solution) were brought to the laboratory and analyzed by ID GC-MS as described above.
For accuracy control in the comparison study, we measured a control sample (Seronorm) with every batch of blood samples analyzed in parallel by both the HemoCue method and the ID GC-MS method. The Seronorm was analyzed by both methods. The accuracy of the HemoCue analyzer was also checked for every sample batch by testing of the control cuvette.
Results and Discussion
Analytical procedure and glycolysis study. The influence of glycolysis when measuring glucose in whole blood is crucial. Depending on the hematocrit, glycolysis reduces the glucose concentration by 7-23% in 1 h and by 25-50% in 4 h after blood collection [14] . This emphasizes that the effect of glycolysis must be eliminated if one is to get correct results when measuring glucose concentration in whole blood. Glycolytic inhibitors such as sodium fluoride reduce the effect of glycolysis only a very little in the first 1-2 h after blood collection [14, 15] . In the case of bedside glucose monitors, which analyze capillary blood immediately after collection, the effect of glycolysis is eliminated. In the method presented here, glycolysis is effectively inhibited when 50 L of capillary blood is taken into 200 L of internal standard solution-as confirmed in a test where glucose was measured in three samples of blood taken into EDTA K 3 -containing tubes (Table 1) . We saw no decrease at all in glucose concentration for 240 min in blood samples so collected; a stable glucose concentration was reached within a few minutes. The standard protocol we propose calls for the samples to be left for 1-2 h after collection of blood to ensure equilibrium between blood glucose and [ 13 C 6 ]glucose before the addition of methanol.
When performing isotope dilution analysis, one must make sure that equilibrium is reached between the internal standard and the substance to be measured. This is especially important for whole blood, which is not homogeneous and differs in glucose concentration between plasma and the erythrocytes. In the method we present, problems with this concentration gradient are overcome by adding 50 L of blood to 200 L of an aqueous solution of the internal standard and mixing thoroughly. The erythrocytes are lysed in this solution and the intracellular glucose is released. We found that deproteinization could be performed 1-2 h after mixing the blood and the internal standard solution because full equilibrium between glucose and [ 13 C 6 ]glucose was achieved in Ͻ1 h. In the glycolysis test, all of the blood samples had normal hematocrit values. Sidebottom et al. [14] showed that, in a blood sample with a hematocrit of 0.43, the glucose concentration decreased ϳ25% in 4 h; in a sample with a hematocrit of 0.75, the glucose concentration decreased ϳ50%. In this test, where we mixed 50 L of whole blood with 200 L of internal standard solution, no decrease in glucose concentration was apparent after 4 h. In view of the dramatic decrease of glucose concentration in nontreated blood samples [14] , we conclude that the inhibition of the glycolysis in the method described is independent of the hematocrit of the blood.
Precision and accuracy. Within-run imprecision was checked by multiple analyses of glucose in whole blood, Seronorm, Pathonorm L, and Pathonorm H ( Table 2) . To check the between-run imprecision, we analyzed Seronorm as a control in different series of blood samples on 36 different days over 10 months. Calculations from these analyses showed that the between-run CV was 1.44% (n ϭ 36). Pathonorm L and Pathonorm H were analyzed similarly, on 19 and 21 different days, respectively. The method showed good precision in all materials and at the three concentration ranges tested.
To check the contribution of the pipetting steps to the imprecision of the method, we weighed 20 empty microcaps and then reweighed them after filling each with 50 L of water at 22°C, calculating from the density of water the volumes delivered by the microcaps. The imprecision (CV) of this pipetting step was 0.44%. The exact volume of this step in the analysis procedure is not crucial because we used the same type of microcap to deliver the standard solutions. The imprecision (CV) of pipetting the internal standard was 0.11%, determined by weighing 20 times The largest contribution to the total imprecision of the method was from sample delivery with the microcap. This sampling technique is nevertheless unavoidable if capillary blood is to be taken. In all concentration ranges (low, normal, and high), the between-run imprecision is low, with CVs of 1.79%, 1.44%, and 1.57%, respectively, and should be compared with the CV limit of 2.0% for a glucose Reference Method proposed in the German program for Quality Assurance in Medical Laboratories [16] .
The accuracy of the method was assessed by analysis of SRM 909b Level I. The accuracy test was performed with standard solutions of glucose prepared from both Specificity. The specificity of the method was checked by analyzing blood from an EDTA K 3 -containing tube that had been gently mixed for a little more than 3 days. The blood was analyzed by the routine protocol described above, and a peak eluting at the same place as glucose, i.e., at 11.41 min, was hardly detectable (Fig. 2B) . When the analysis was carried out without the addition of [ 13 C 6 ]glucose, no peak at all could be seen at the elution position of glucose (Fig. 2A) . The small glucose peak seen in Fig. 2B , which probably originates from trace amounts of glucose in the [ 13 C 6 ]glucose batch used, was estimated as 0.2% of the amount of [ 13 C 6 ]glucose added. The peak corresponds to a glucose concentration of Ͻ0.01 mmol/L and its contribution to quantification of glucose in blood can be neglected. We conclude that the method is highly specific for analyzing glucose in whole blood. analyzer (comparison method) for a total of 496 blood samples. Of the results from all six instruments, 23% to 59% deviated by Ͼ15% from the comparison method.
In conclusion, the method described is to our knowledge the first ID GC-MS technique adopted for analysis of glucose in capillary whole blood. We used it to assess the accuracy of a bedside whole-blood glucose analyzer. To be able to use the ID GC-MS method as a Reference Method for bedside glucose determination, we adjusted the analysis procedure to better fit the clinical circumstances. The ID GC-MS protocol is easy to follow, and both precision and accuracy are good enough to regard the method as a Reference Method for whole-blood glucose determinations.
The excellent technical assistance of Liisa Norrgren is gratefully acknowledged. We also thank HemoCue AB for the loan of the instrument and for the support of free cuvettes.
